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Abstract: Angiogenesis, the formation of new blood vessels, is critical for survival and in
the regenerative response to tissue injury or ischemia. However, in diseases such as cancer
and atherosclerosis, inflammation can cause unregulated angiogenesis leading to excessive
neovascularization, which exacerbates disease. Current anti-angiogenic therapies cause complete
inhibition of both inflammatory and ischemia driven angiogenesis causing a range of side effects
in patients. Specific inhibition of inflammation-driven angiogenesis would therefore be immensely
valuable. Increasing evidence suggests that the CC-chemokine class promotes inflammation-driven
angiogenesis, whilst there is little evidence for a role in ischemia-mediated angiogenesis. The differential
regulation of angiogenesis by CC-chemokines suggests it may provide an alternate strategy to treat
angiogenesis associated pathological diseases. The focus of this review is to highlight the significant
role of the CC-chemokine class in inflammation, versus ischemia driven angiogenesis, and to discuss
the related pathologies including atherosclerosis, cancer, and rheumatoid arthritis. We examine the
pros and cons of anti-angiogenic therapies currently in clinical trials. We also reveal novel therapeutic
strategies that cause broad-spectrum inhibition of the CC-chemokine class that may have future
potential for the specific inhibition of inflammatory angiogenesis.
Keywords: angiogenesis; chemokines; inflammation; ischemia
1. Introduction
Angiogenesis is the formation of new blood vessels from pre-existing blood vessels [1]. It is
an essential process for development, growth, and repair. Under postnatal physiological conditions,
angiogenesis is important for tissue neovascularization in response to ischemia (e.g., following
myocardial infarction and in peripheral vascular disease) and in repair during wound healing.
In contrast, uncontrolled regulation of angiogenesis that occurs with excessive or prolonged
inflammation can lead to the promotion of pathological angiogenesis that is associated with the
acceleration of diseases such as cancer and atherosclerosis. Increasing evidence implicates chemokines
as key regulators of angiogenesis. Several members of the CC-chemokine class are implicated in
a number of diseases in which inflammation-induced pathological angiogenesis plays an important
role. Inflammatory angiogenesis is not, however, exclusive to the CC-chemokine class and members
of the CXC and CX3C classes also play a role. Some CXC-chemokines, including those which bind
to CXCR2 (and CXCR1 in humans), are also known to promote inflammation-driven angiogenesis.
For example, CXCL5 and CXCL8 which bind to CXCR2 promote angiogenesis [2], while CXCL4 and
CXCL10, which bind to CXCR3 inhibit angiogenesis in the context of inflammation [3]. Furthermore,
in vitro studies have shown that the CX3C chemokine CX3CL1 (fractalkine) is a stimulator of angiogenic
functions such as endothelial cell migration, proliferation and tubulogenesis [4].
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Inflammation-driven diseases associated with angiogenesis are highly prevalent globally, with
cardiovascular related disorders and cancer being the leading causes of mortality worldwide [5].
Current anti-angiogenic therapies suppress angiogenesis in all pathophysiological conditions,
and while many are successful in suppressing disease progression, they often cause severe side effects
including high blood pressure and gastrointestinal disorders [6,7]. This highlights the need for novel
therapeutic targets and/or strategies that can specifically inhibit inflammation-driven angiogenesis
while having no effect on important physiological ischemia-mediated angiogenic processes.
2. Conditional Regulation of Angiogenesis
The regulation of angiogenesis involves a number of critical growth factors, cytokines,
signaling cascades and cellular processes that are triggered in response to either an inflammatory or
ischemic stimulus. Inflammatory and ischemia-driven angiogenesis are regulated via two distinctly
different, yet slightly overlapping pathways [8]. Inflammation-driven pathological angiogenesis
accelerates a number of disease processes, in particular tumor growth in cancer and plaque expansion
in atherosclerosis through intra-plaque neovascularization [8–10]. Inflammatory angiogenesis also
exacerbates rheumatoid arthritis [11]. A key promoter in the inflammatory angiogenic pathway is the
transcription factor nuclear factor-κB (NF-κB). Whilst, in ischemia-induced physiological angiogenesis
that is critical for wound healing or following a myocardial infarction to promote re-oxygenation of
the heart tissues, the transcription factor, hypoxia inducible transcription factor-1α (HIF-1α), is the
key promoter. Interestingly, vascular endothelial growth factor (VEGF) is a key promoter of both
inflammation-driven pathological angiogenesis and ischemia-induced physiological angiogenesis.
This is possible because VEGF has response elements for both NF-κB and HIF-1α in its promoter
region (Figure 1), allowing for activation of its production from both signaling pathways [12–15].
HIF-1α also possesses a response element for NF-κB signaling [16]. By having both NF-κB and
hypoxia response elements (HREs) in the promoter regions of HIF-1α and VEGF, it enables conditional
regulation of angiogenesis. This implies for example that specific suppression of inflammatory
angiogenesis will not prevent the induction of physiological ischemia-driven angiogenesis via the
HREs. Whilst inflammatory and ischemia-driven angiogenesis are regulated by distinct pathways,
these two forms of angiogenesis are likely to co-exist. In atherosclerosis and in tumors, as the
plaque/tumor grow, cells become distant to nearby vessels creating hypoxic regions that are the initial
triggers for neovascularization. Plaque/tumor neovessels then deliver inflammatory cells/cytokines to
the site and inflammation becomes the predominate driving force in the progression of the disease [17].
2.1. Pathological Inflammatory Angiogenesis
Pathological angiogenesis is induced at sites of vascular inflammation where there has
been increased recruitment of monocytes/macrophages. Macrophages are potent promoters of
angiogenesis as they release pro-angiogenic factors, including VEGF, basic fibroblast growth factor
(bFGF), platelet derived growth factor (PDGF), tumor necrosis factor-α (TNF-α) and interferon-γ
(IFN-γ) that then stimulate excessive neovessel formation [18–20]. In plaques, tumors and in RA,
neovessels facilitate increased transportation of more inflammatory cells, cytokines and growth
factors to the site and exacerbate the disease further [9,10,21]. Neovessels in atherosclerotic plaques
are particularly undesirable as they are thin walled and prone to hemorrhage making the plaque
unstable [22]. Tumor neovessels also have undesirable effects and lead to metastasis as the local
lymphatic systems are unable to support the tumor expansion and shunt tumor cells to neighboring
lymph nodes.
An increase in inflammation can also directly cause the stimulation of angiogenesis in endothelial
cells. Under inflammatory conditions, vessels form dense and highly disorganized networks [23].
These new vessels develop from existing vessels in which endothelial cells are recruited from sites
adjacent to the injury [24]. These recruited endothelial cells accelerate angiogenesis either by forming
part of the new vessel or by stimulating vessel growth in a paracrine fashion. At inflammatory
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sites in tumors, fibroblasts aid in the remodeling of the extracellular matrix (ECM) to make way for
new vessels and have also been shown to have pro-angiogenic properties and promote rapid tumor
growth and metastasis [21,25,26]. Due to the imbalance between the pro- and anti-angiogenic switch,
pathological angiogenesis persists and exacerbates the disease, preventing its resolution.
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Figure 1. The conditional regulation of vascular endothelial growth factor (VEGF) in inflammation and
ischemia. An inflammatory stimulus activates the PI3K/Akt pathway, leading to the phosphorylation
of IκBα. IκBα is degraded allowing NF-κB subunits, p50 and p65 to translocate into the nucleus and
activate the production of VEGF. Whereas, ischemia activates the PI3K/Akt pathway to increase
the production of Siah1 and Siah2, causing the degradation of PHD1-3 preventing the targeted
degradation of HIF-1α, allowing it to accumulate and then translocate to the nucleus where it
upregulates VEGF production.
2.2. Physiological Ischemia-Driven Angiogenesis
Physiological angiogenesis is primarily triggered when there is a chronic imbalance in tissue
oxygen supply versus demand following injury or vessel occlusions, which restricts the supply of blood.
Neovessel growth is triggered via signaling through HIF-1α. HIF-1α is regulated post-translationally
by the prolyl hydroxylase domain protein family (PHD1, PHD2, PHD3). Under high oxygen conditions,
PHDs are upregulated causing ubiquitination and degradation of HIF-1α [27,28]. Whilst in low oxygen
conditions, E3 ubiquitin ligases Siah1 and Siah2 are upregulated resulting in the degradation of PHD1-3
leading to stabilization and accumulation of HIF-1α [29,30]. This enables the translocation of HIF-1α
into the nucleus, where it complexes with the HIF-1β subunit to bind to the hypoxia response element
(HRE). HIF-1α upregulates pro-angiogenic growth factors including a 30-fold increase in VEGF [29,30].
HIF-1α is essential in physiological angiogenesis. For example, inactivation of HIF-1α in mice results
in abnormal vascular developmental and embryonic lethality [31–34].
Endothelial nitric oxide synthase (eNOS) is a key enzyme responsible for the promotion of
angiogenesis in ischemia and is downstream of VEGF Receptor 2 (VEGFR2), the main receptor for
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angiogenesis, following activation by VEGF. Upon ischemic induction, eNOS stimulates the production
of nitric oxide (NO), which directly promotes angiogenic processes. NO also controls the expression
of growth factors such as VEGF, angiopoietins, and fibroblast growth factors and genes involved in
matrix metabolism, including matrix metalloproteinases [35].
The important angiogenic functions are cell migration, proliferation and tubulogenesis, which are
induced by both hypoxic and inflammatory stimuli [36,37]. Under each stimulus, endothelial cells
undergo increased proliferation and migration prior to assembling into tubular structures to form
new blood vessels. During angiogenesis, circulating endothelial progenitor cells (EPCs) from the bone
marrow promote angiogenesis in a paracrine fashion by secreting growth factors and cytokines to
activate local endothelial cells for angiogenesis [38–40]. EPCs have also been shown to incorporate
into tubules and participate in angiogenesis directly [41,42].
3. Chemokines
Increasing evidence suggests that small (8–12 kDa) inflammatory cytokines known as chemokines
are key regulators of angiogenesis. The main role of chemokines is to direct the recruitment and
migration of cells to sites of inflammation or injury. They are divided into four classes according to
the placement and number of the cysteine residues at the amino terminus. The CC chemokine group
has two cysteine residues adjacent to each other, the CXC chemokine group has two cysteine residues
separated by an amino acid. The CX3C chemokine group has three amino acids between two cysteine
residues and the C chemokine group has only one cysteine residue at the amino terminus [43–45].
Of the four chemokine groups, the largest are the CC-chemokines consisting of 28 members in
total across all species. This is followed by the CXC-chemokines (17 members), with the CX3C- and
XC-chemokines having one and two members respectively.
Under homeostatic conditions, some chemokines such as CCL19 and CCL21, are constitutively
expressed in cells to assist with basal leukocyte migration [46,47]. Other chemokines such as CCL2,
CCL3, CCL4 and CCL5 are expressed when induced by an inflammatory stimulus [47]. Endothelial
cells are able to generate and release chemokines under normal and inflammatory conditions and this is
likely the major source of chemokines found on the luminal surface of the endothelium [48]. Once at the
luminal surface, chemokines will first bind to glycosaminoglycans (GAGs) such as heparin and heparin
sulfate, present on the surface of endothelial cells. Chemokines will then start to accumulate at the site
of inflammation/injury via GAG attachment. This is essential, as many chemokines cannot recruit cells
unless they are bound to GAGs [49]. GAGs are highly negatively charged and form an electrostatic
interaction with the basic chemokine [50], tethering the chemokines to the cell surface ready for
receptor interaction. GAG binding also causes oligomerization which is thought to be important in
establishing chemokine activity but not receptor interaction [49,51]. Chemokine retention on the cell
surface configures a concentration gradient which attracts leukocytes and monocytes to the area of
inflammation or injury [52]. CC-chemokines bind to and activate inflammatory cells (e.g., monocytes,
neutrophils) via binding to their cognate receptors. Receptor attachment causes a conformation change
of the CC-chemokine, leading to an essential receptor and CC-chemokine N-terminal interaction that
activates the inflammatory cell [44,51].
Interestingly, there is promiscuity in chemokine signaling, where chemokines in one class can bind
to several receptors from the same class [53–55]. Conversely, receptors can have multiple ligands within
a chemokine class [53–55]. For example in humans, CCR2 can bind CCL2, CCL7, CCL8, CCL13 and
CCL16, whilst CCR5 can bind CCL3, CCL4, CCL5, CCL8, CCL11, CCL13, CCL14 and CCL16 [53–55].
Chemokine promiscuity is essential for the chemokine network as it allows for the robust control of
the inflammatory system, such that if one chemokine is inhibited another may replace its function.
4. Chemokines in Angiogenesis Associated Diseases
In addition to their role in maintaining immune cell homeostasis, some chemokines have
also been shown to have roles in the development of and, in particular, the promotion of
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angiogenesis. Several members of the CC-chemokine class including CCL1, CCL2, CCL5, CCL11,
CCL15 and CCL16 [56–60] are involved in stimulating pathological inflammation-driven angiogenesis,
with little evidence for a role in ischemia-mediated physiological angiogenesis. In contrast,
a member of the CXC-chemokine class, CXCL12, uniquely plays an important role in physiological
hypoxia-mediated angiogenesis.
4.1. CC-Chemokines in Pathological Inflammation-Driven Angiogenesis
CC-chemokines are increasingly implicated in disease pathologies in which inflammation-driven
angiogenesis plays a key role (Figure 2). They are primarily known to promote angiogenesis indirectly
by first recruiting macrophages to the site of inflammation or injury where they then release
pro-inflammatory cytokines and growth factors that lead to neovessel formation. For example in liver
fibrosis, angiogenesis is caused by macrophage recruitment directed by CCL2 [61]. In inflammatory
conditions, CC-chemokines are secreted by a wide variety of cells including endothelial cells,
smooth muscle cells and inflammatory cells.
Recent evidence demonstrates that CC-chemokines can also directly regulate inflammation-driven
angiogenesis. For example, CC-chemokines have been shown to promote signaling pathways which
induce inflammation-driven angiogenesis including the signaling proteins phosphatidylinositol
3-kinase (PI3K), Akt and mitogen-activated protein kinase (MAPK) and ERK1/2 to increase nitric
oxide production, and endothelial cell proliferation and migration, ultimately leading to increased
angiogenesis [56,62]. Stimulation of these pathways subsequently increases the production of VEGF
to further augment neovascularization [56,62]. Additionally, CCL2 is associated with the increase of
MMP14, essential for endothelial cell migration and neovessel formation [62]. CCL2 has also been
shown to accelerate endothelialization through the recruitment of EPCs [63]. Endothelial tubule
formation in vitro is increased following incubation with CCL1, CCL2, CCL11, CCL15 and
CCL16 [56–60]. Furthermore, all CC-chemokines contain NF-κB binding motifs and their expression is
dramatically increased under inflammatory conditions [54,64,65].
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Figure 2. Regulation of inflammation-driven pathological angiogenesis by CC-chemokines.
CC-chemokines regulate angiogenesis through two pathways: (1) the direct pathway; and (2) the indirect
pathway. (1) Red Arrows - Direct stimulation by CC-chemokines promotes signali g pathways such as
PI3K, MAPK, and ERK1/2 to incr se nitric xide production and promote endothelial cell proliferation
and migration leading to neovessel formation; (2) Green Arrows - Indirect stimulation involves the initial
recruitment of macrophages to the site of inflammation by CC-chemokines, which secrete pro-angiogenic
factors such as VEGF, bFGF, PDGF, TNF-α and IFN-γ that promote angiogenesis.
Int. J. Mol. Sci. 2016, 17, 1856 6 of 16
4.1.1. CC-Chemokines in Atherosclerosis
Atherosclerosis is a chronic inflammatory disease associated with the recruitment of circulating
leukocytes into the vascular wall. Inflammation-driven angiogenesis accelerates plaque formation
as intra-plaque neovessels deliver more inflammatory cells to the plaque. Plaque neovessels are also
fragile and prone to rupture, thereby significantly contributing to plaque instability [9]. Atherosclerosis
develops over several decades and encompasses a host of cellular processes involved at various
stages of disease from the initiation of plaque formation to plaque rupture, with NF-κB shown to be
the key transcription factor involved throughout the entire disease progression. The initial stage of
atherosclerosis involves damage to the endothelium and the activation of endothelial cells via the
NF-κB signaling pathway. This results in the expression of adhesion molecules and various chemokines
such as CCL2, CCL5, macrophage inflammatory factor (MIF), and CX3CL1 [66–68], that promote the
recruitment of leukocytes to the vascular intima.
A number of CC-chemokines have been identified in human atherosclerotic plaques, including:
CCL2, CCL3, CCL5, CCL11, CCL13, CCL18, CCL19, thereby suggesting a role for them in plaque
neovessel formation [69–72]. Furthermore, targeted CC-chemokine receptor or CC-chemokine
deletion studies in atherosclerosis-prone ApoE−/− mice have found they develop significantly less
plaque [73–75]. For example, Met-RANTES (an antagonist to CCL5) causes reductions in the size
of atherosclerotic lesions in hypercholesterolemic LDLR−/− mice [73–75]. Mice deficient in CCR5,
the receptor for CCL5, is associated with reduced macrophage accumulation and fewer more stable
plaques [76]. Conversely, overexpression of CCL2 induces macrophage infiltration and enhances
atherosclerosis in ApoE−/− mice [77]. Recently, a phase II clinical trial using a CCR2 neutralizing
antibody MLN1202 found a decrease in C-reactive protein in patients with high risk of atherosclerosis,
suggesting the potential for the suppression of inflammation, plaque angiogenesis and ultimately
plaque progression [78].
4.1.2. CC-Chemokines in Rheumatoid Arthritis
Studies have shown that in rheumatoid arthritis (RA), another inflammation-driven pathology,
new blood vessels are abundant in the synovial tissue. Neovessels promote the infiltration of leukocytes
that increase the progression of RA [11]. Previous studies have found that production of CCL2, CCL3,
CCL5, and CCL20 are associated with increased leukocyte infiltration and angiogenesis in models of
RA [11,79,80]. Despite the high levels of expression of CC-chemokines in RA, two separate clinical
trials with MK-0812 and MLN1202, both CCR2 antagonists, were found to be ineffective [81,82].
Similarly targeting single CC-chemokine receptors CCR1 with Pfizer’s CP-481,715, and CCR5 with
Maraviroc were also ineffective [83,84]. Some promising findings have, however, been demonstrated
with CCX354-C, a CCR1 antagonist, that improved RA by 20% in 56% of patients after receiving a daily
200 mg dose [85].
4.2. Chemokines in Physiological Ischemia-Mediated Angiogenesis
In contrast to their critical role in inflammation-driven angiogenesis, the CC-chemokines
have little involvement in ischemia-mediated angiogenesis (Figure 3). It is the CXC-chemokines,
and in particular CXCL12 (also known as stromal-cell derived factor-1α, SDF-1α), that are involved
in important developmental processes including hematopoiesis, organogenesis and tissue repair.
This is highlighted by the fact that CXCL12 knockout mice are not viable due to the absence
of vessel development [86]. HIF-1α augments the increase in expression of CXCL12 in ischemia.
Consistent with this, CXCL12 expression in ischemic sites directly correlates with the degree of
hypoxia [87]. Furthermore, increased CXCL12 levels have been reported in infarcted myocardium
in both human and rodent studies, with increased CXCL12 levels detected as early as 1 h following
ischemic induction in the myocardium or in hindlimbs, indicative of a role in the initiation of tissue
repair and revascularization [88–90]. CXCL12 is the single natural ligand for the chemokine receptor
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CXCR4 [91] and the CXCL12/CXCR4 axis is important in the mobilization, migration and recruitment
of EPCs to sites of ischemia [86,92–95]. Mechanistically, CXCL12 mobilizes bone marrow-derived
EPCs by enhancing PI3K/Akt/eNOS activation [96]. Upregulation of eNOS further promotes EPC
mobilization by increasing the production of VEGF [97].
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Figure 3. Regulation of ischemia-mediated physiological angiogenesis by the CXC-chemokine CXCL12.
Increased HIF-1α in response to ischemia causes the release of CXCL12 and VEGF, leading to
increased nitric oxide production and augmented endothelial migration and proliferation to promote
angiogenesis. Furthermore, CXCL12 upregulates the recruitment and mobilization of EPCs to sites of
ischemia. Increased nitric oxide from the induction of CXCL12 further mobilizes EPCs and increases
the production of VEGF for neovessel formation.
5. CC-Chemokines in Cancer
Tumor angiogenesis is triggered initially by inflammation and then promoted further by
hypoxia. Tumor neovessels facilitate the recruitment of inflammatory cells that express pro-angiogenic
mediators. This promotes a positive angiogenic feed-forward loop, similar to that of plaque
neovessels. Tumor angiogenesis is regarded as a negative prognostic variable for several malignancies
including breast and prostate cancer [98–100]. CC-chemokines have been associated with a number of
malignancies. Studies reveal that CCL2 and CCL5 expression are elevated in breast and prostate
cancer [101,102]. CCL1 and CCL3 are shown to promote development of leukemia and CCL19,
CCL21, and CCL25 direct tumor metastasis [103,104]. Murine cancer models have demonstrated the
importance of CC-chemokines in tumor development in vivo. Inhibition of CCL2 reduced hemangioma
size in nude mice inoculated with cancer cells, while infusion of Met-RANTES inhibited tumor
development in murine models of breast cancer [105].
In the progression of tumor development, tumors expand to become solid tumors, causing the
microenvironment to become progressively more hypoxic as cells become distant to nearby vessels.
This forces cancer cells to adapt promoting tumorigenesis so oxygen and other nutrients can be
delivered, expanding the tumor further. This also enhances tumor malignancy and aggressiveness,
ultimately resulting in increased resistance to therapy and poor long-term prognosis. This response
is induced by a series of hypoxia-mediated proteomic and genomic changes that facilitate cell
survival [106]. CC-chemokines are not the only chemokines found in tumors. The CXC-chemokine
class have also been shown to play a role in tumor neovascularization. For example, IL-8 (CXCL8)
promotes tumor growth, angiogenesis and metastasis [107]. Furthermore, CXCL12 production is
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triggered in hypoxic environments in tumor cells [108] and is implicated in the promotion of tumor
growth in mouse prostate tumors following overexpression of its receptor CXCR4 [109].
6. Anti-Angiogenic Therapies
The development of anti-angiogenic agents is of great interest due to the high prevalence of
diseases associated with angiogenesis. Current anti-angiogenic agents such as VEGF inhibitors or VEGF
receptor inhibitors are found to reduce atherosclerotic plaque size and tumor growth in a variety of
malignancies including breast, lung and prostate cancers [10,43,110–112]. However, the VEGF signaling
pathway is critically important in physiological ischemia-driven angiogenesis as well as other biological
functions (e.g., regulation of blood pressure, activation of the coagulation cascade, and regulation
of myelopoiesis [113–116]) so non-specific inhibition of VEGF in all pathophysiological contexts
leads to side effects including: bleeding, vessel clots (leading to stroke or heart attack), proteinuria,
severe weight loss, hypertension, diarrhea, nausea gastrointestinal perforations, and reduced wound
healing [6,7,117,118]. Furthermore, the clinically available Bevacizumab (an anti-vascular endothelial
growth factor, VEGF, antibody) [119] and multi-targeted tyrosine kinase inhibitors (TKIs, target the
VEGF receptor), such as Sorafenib and Sunitinib [120], cause endothelial dysfunction and capillary
rarefaction [6,7,117]. Both classes of drug cause clinically significant elevations in blood pressure
(12%–15%), bleeding and hemorrhage—all of which are associated with impaired regenerative
angiogenic responses [6,7,117]. These studies suggest that complete inhibition of angiogenesis may
not be the ideal strategy to suppress pathological angiogenic diseases. This highlights the need for the
development of novel therapies specifically targeting only pathological angiogenesis whilst preserving
physiological angiogenesis.
Other than VEGF inhibitors, on-going clinical trials that target individual CC-chemokine receptors
have shown some success, including: (1) MLN1202 that targets CCR2 and causes reductions in circulating
C-reactive protein in patients with high risk of atherosclerosis; and (2) Mogamulizumab that targets
CCR4 and causes reductions in regulatory T cells in patients with adult T-cell leukemia-lymphoma (ATL)
and peripheral T-cell lymphoma [81,121]. However due to the promiscuity in chemokine signaling the
inhibition of a single chemokine receptor may not be entirely efficacious [122,123]. An agent capable of
simultaneously targeting multiple chemokines is likely to provide a more effective approach. Due to
their specific role in inflammation-driven angiogenesis, targeting of the CC-chemokine class as a whole
may provide a unique means of inhibiting only pathological angiogenesis without affecting critical
physiological angiogenic functions.
Broad-Spectrum CC-Chemokine Inhibition as a Strategy to Inhibit Pathological Angiogenesis
Broad-spectrum chemokine inhibitors, also called chemokine binding proteins, have been
found to be expressed from a range of species including the Schistosoma mansoni helminth worm,
the Rhipicephalus sanguineus tick and several viruses. Chemokine binding proteins are thought to
have evolved as a way to bypass the host inflammatory response to propagate their infection.
These chemokine binding proteins target multiple chemokines. For example, the S. mansoni chemokine
binding protein (smCKBP), secreted from schistosome eggs, targets CXCL8, CCL2, CCL3, CCL5 and
CX3CL1 [124]. Chemokine binding proteins from R. sanguineus tick, called Evasins, bind to (Evasin-1)
CCL3, CCL4, CCL5, (Evasin-3) CXCL1, CXCL2, CXCL3, CXL5, CXCL6, CXCL8, (Evasin-4) CCL5 and
CCL11 [125]. Viral protein M3 from the mouse herpes virus binds to several inflammatory chemokines
across all four classes by binding to GAGs and chemokines such as XCL1, CCL2, CCL5, CXCL8 and
CX3CL1 [126–128]. Vaccinia viral protein “35K” is another chemokine binding protein that uniquely
binds with high affinity to the CC-chemokine class [129–133]. 35K has been shown to suppress
inflammation-driven diseases in pre-clinical models including atherosclerosis [134–136], liver fibrosis
and acute peritonitis [137,138]. Additionally, 35K attached to a Fc fusion protein (35K-Fc) improved
pulmonary function and reduced inflammation in the lung [139]. 35K will therefore not inhibit
CXCL12 which is essential for development and for tissue repair following ischemia. Broad-spectrum
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inhibition of the CC-chemokine class by 35K may be an alternate therapeutic strategy to specifically
reduce pathological angiogenesis-associated diseases such as atherosclerosis and cancer, without
the severe side effects of current non-selective angiogenic inhibitors that block angiogenesis in all
pathophysiological contexts, including in ischemia.
In support of this concept, administration of CCL2 increases inflammatory angiogenesis in
mice [140] and induces inflammatory angiogenesis in rabbit cornea [141]. In contrast, CCL2−/−
mice show no difference in capillary density compared to wild type mice in a model of myocardial
ischemia [142]. Furthermore, CCR2−/− mice have comparatively normal revascularization in the
hindlimb ischemia model, compared to wild type mice [143]. Unpublished studies from our
laboratory have found that mice injected with adenovirus overexpressing 35K (Ad35K) have reduced
neovessel formation in the peri-arterial femoral cuff model of inflammation-driven angiogenesis,
when compared to mice injected with control GFP adenovirus (AdGFP). In contrast, we found
angiogenesis was preserved in the hindlimb model of ischemia-mediated angiogenesis following
CC-chemokine class inhibition with 35K. In vitro functional assays of angiogenesis supported
these findings. 35K inhibited endothelial cell proliferation, migration and tubule formation in
inflammatory conditions but, conversely, had minimal effects on these angiogenic functions in
hypoxia. Mechanistically, we revealed that VEGF was conditionally regulated by 35K, where VEGF
is suppressed in inflammation but preserved in hypoxia (Unpublished data). The ability of 35K to
inhibit inflammation-driven angiogenesis whilst preserving ischemia-mediated angiogenesis suggests
it may present as an alternate therapeutic strategy for the specific inhibition of diseases associated with
inflammatory driven angiogenesis.
7. Conclusions
In conclusion, CC-chemokines play an important role in inflammation-driven pathological
angiogenesis whilst having minimal effects in ischemia-mediated physiological angiogenesis.
This differential regulation of angiogenesis by CC-chemokines highlights the possibility that targeted
inhibition of CC-chemokines will prevent inflammation-driven angiogenesis, whilst preserving
important ischemia-mediated angiogenic processes. Current strategies targeting VEGF or single
CC-chemokines/receptors have caused issues including severe side effects or ineffectiveness. This is
likely due to the complete inhibition of VEGF across all pathophysiological contexts and also the
promiscuity in chemokine signaling, respectively. A new approach for a more targeted strategy is
broad-spectrum CC-chemokine class inhibition and there is recent evidence that it specifically inhibits
pathological angiogenesis, whilst leaving the physiological angiogenesis unchanged. This may have
immense benefits over current anti-angiogenic therapies.
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